GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.1 million of its common stock and warrants to purchase common stock in a registered direct offering.

GERMANTOWN，Md.，2023年11月8日（GLOBE NEWSWIRE）-Orgenesis Inc.（“Orgenesis”）（纳斯达克：ORGS），一家全球生物技术公司，致力于发挥细胞和基因疗法（CGT）的全部潜力，今天宣布，它已与一位机构投资者签订证券购买协议，购买约110万美元的普通股，并保证在注册直接发行中购买普通股。

The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $0.78. Under the terms of the securities purchase agreement, Orgenesis has agreed to issue 1,410,256 shares of common stock and warrants to purchase up to an aggregate of 1,410,256 shares of common stock (the “Warrants”).

每股普通股及相关认股权证购买一股普通股的合并有效购买价格为0.78美元。根据证券购买协议条款，Orgenesis已同意发行1410256股普通股股份，并保证购买多达1410256股普通股股份（“认股权证”）。

The Warrants will be exercisable immediately following the date of issuance and may be exercised for a period of five years from the initial exercisability date at an exercise price of $0.78 per share. Titan Partners Group, a division of American Capital Partners, is acting as sole placement agent for the offering.

认股权证将于发行日期后立即行使，并可于最初行使日期起行使五年，行使价为每股0.78元。美国资本合作伙伴的分公司Titan Partners Group正在担任该产品的独家代理商。

The offering is expected to close on or about November 9, 2023, subject to the satisfaction of customary closing conditions. The shares of common stock and Warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-254806) previously filed on March 26, 2021 and declared effective by the Securities and Exchange Commission (“SEC”) on April 7, 2021.

在满足习惯性关闭条件的前提下，预计该产品将于2023年11月9日或之后关闭。普通股和认股权证的股份是根据先前于2021年3月26日提交并由证券交易委员会（“SEC”）宣布生效的表格S-3（文件号333-254806）的货架登记声明提供的。2021年4月7日。

The offering of the shares of common stock and Warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s web.

普通股和认股权证股份的发行只能通过构成登记声明一部分的IPO补充资料进行。如果可以的话，可以在美国证券交易委员会的网上获得与此产品相关的IPO补充说明和随附的IPO副本。